HomeFUNDING
FUNDING
Medical device and diagnostics companies are always looking for ways to improve their products and services. In the ever-changing landscape of the healthcare industry, it’s essential for these companies to stay ahead of the curve. That’s why funding is always news.
Series A, B, and other rounds of funding are essential for medical device and diagnostics companies. They provide the necessary capital to help these businesses grow and innovate. And with so many investors interested in this space, there are plenty of opportunities for companies to secure the funding they need.
R3 Vascular Announces $87 Million in Series B Financing
R3 Vascular will use the proceeds to support the ELITE FDA IDE pivotal trial of its best-in-class bioresorbable scaffold, MAGNITUDE®, for below-the-knee (BTK) PAD.
Nami Surgical Secures Investment to Transform Robotic-Assisted Surgery Market
Nami Surgical develops miniaturised ultrasonic medical devices for surgical applications, and supports medical device companies to deliver innovation in ultrasonic surgery. In a groundbreaking development, Nami has introduced a high-performance, miniaturised ultrasonic scalpel, overcoming significant barriers in robotic-assisted surgery. Traditionally favoured in laparoscopic procedures, ultrasonic scalpels have been too large for effective use in robotic surgery until now.
AISAP Raises $13 Million in Seed Funding for First AI-Powered, Point Of Care Ultrasound Diagnostic Solution
"Obtaining an accurate ultrasound diagnosis in time can literally be the difference between life and death, so the fact that so many patients are forced to wait up to a month for one is nothing short of a global health crisis," says AISAP CEO Roni Attali. "This problem is particularly acute in rural areas or those with fewer resources, and therefore disproportionately impacts disadvantaged populations."
Vitestro Secures $22 Million (€20 million) for Autonomous Blood Draw Device
Co-led by return investor Sonder Capital and new investor NYBC Ventures, with participation from Invest-NL, the European Innovation Council Fund (EIC Fund), and existing private investors, the oversubscribed funding round will support Vitestro’s commercialization in Europe and its organizational expansion into the U.S. market.
E Tech Group Secures New Investment from Graham Partners, Sets Stage for Continued Growth and Innovation
With this new investment partnership, E Tech Group expects to accelerate organic growth and acquisition to become a top system integrator in North America.
ROM InWest Invests €1.5 million into AI and Computer Vision Company Kepler Vision Technologies
The investment will allow ROM InWest to further distribute its fall detection product globally.
Sensorion Announces a €15 Million Financing, Extending Cash Runway Until the End of 2025
Nawal Ouzren, Sensorion’s Chief Executive Officer, said: “We are thrilled to announce another successful capital raise, securing an additional EUR 15 million to accommodate interest expressed by certain existing investors. This builds on the earlier EUR 50 million financing announced in February 2024, adding up to a total of EUR 100 million raised in less than 9 months. With this new financing, we are well-positioned to accelerate our gene therapy programs, including the progression of SENS-501 through its Phase 1/2 clinical study, Audiogene, and the advancement of our second program, GJB2-GT, towards Clinical Trial Applications submission in H1 2025. The capital increase enables the Company to finance its activities until the end of 2025. We remain deeply thankful for the ongoing support of our shareholders and partners as we strive to make a meaningful difference in the lives of those affected by hearing loss disorders.”
Kryptos Biotechnologies Secures $10 Mil in Series A Funding | Funds to Be Used for Clinical Studies and FDA Approval of their Molecular...
Strategic Investor, Osang Healthcare will partner with Kryptos Biotechnologies for the manufacturing and distribution of the product along with financing.
Obsidian Therapeutics Announces Oversubscribed $160.5 Million Series C Financing to Drive OBX-115 Clinical Development
Proceeds from the financing will advance Obsidian’s lead engineered tumor-infiltrating lymphocyte (TIL) program, OBX-115, in its ongoing trials for patients with melanoma and non-small cell lung cancer (NSCLC). Obsidian Therapeutics is focused on enrolling patients and reaching key clinical and regulatory milestones, as well as manufacturing scale-up ahead of pivotal trial readiness.